Month: January 2023
LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody being developed for solid tumors Excerpt from the Press Release: BOSTON and LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has received…
Read More
Excerpt from the Press Release: BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has engaged Avania as the contract research organization (CRO) for the Company’s pilot clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology…
Read More
Excerpt from the Press Release: CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research. Dr. Bennett shares this year’s prize with Don W. Cleveland, Ph.D., chair…
Read More
– Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg – – Meaningful clinical benefit was observed in FolRα-selected patients, defined as TPS>25%, which is potentially…
Read More
U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for…
Read More
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition Excerpt from the Press Release: WALTHAM, Mass., Jan.…
Read More
First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway. Excerpt from the Press Release: WALTHAM, Mass. (January 10, 2023) – ScipherMedicine, a precision immunology company matching each patient with their most effective therapy, has acquired Philadelphia-based data, analytics, and software company CrossBridge to bolster its data and analytics capabilities. The…
Read More
Excerpt from the Press Release: SAN DIEGO, Jan. 10, 2023 /PRNewswire/ — Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor (CAR) that targets overexpression of BT-001 antigen present on various types of solid tumors. The CAR-T (B4t2-001) was developed from Bio4t2’s PrismCore™ platform. “This first-in-human study marks the initial therapeutic to…
Read More
Excerpt from the Press Release: MADRID, Spain and BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in a Phase II collaborative study with iadademstat in…
Read More
Excerpt from the Press Release: PRINCETON, N.J., January 18, 2023 – Taiho Oncology, Inc. today announced the publication of results from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in the January 19, 2023 issue of The New England Journal of Medicine (NEJM). The article, “Futibatinib for Intrahepatic Cholangiocarcinoma with FGFR2 Fusions/Rearrangements,” reports on…
Read More